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In recent years, the panel of known molecular mutations in acute lymphoblastic leukemia (ALL) has been continuously increased.
InPhiladelphia-positiveALL,deletionsoftheIKZF1genewereidentiﬁedasprognosticallyadversefactors.Theseimprovedinsights
in the molecular background and the clinical heterogeneity of distinct cytogenetic subgroups may allow most diﬀerentiated
therapeutic decisions, for example, with respect to the indication to allogeneic HSCT within genetically deﬁned ALL subtypes.
Quantitative real-time PCR allows highly sensitive monitoring of the minimal residual disease (MRD) load, either based on
reciprocal gene fusions or immune gene rearrangements. Molecular diagnostics provided the basis for targeted therapy concepts,
for example, combining the tyrosine kinase inhibitor imatinib with chemotherapy in patients with Philadelphia-positive ALL.
Screening for BCR-ABL1 mutations in Philadelphia-positive ALL allows to identify patients who may beneﬁt from second-
generation tyrosine kinase inhibitors or from novel compounds targeting the T315I mutation. Considering the central role
of the molecular techniques for the management of patients with ALL, eﬀorts should be made to facilitate and harmonize
immunophenotyping,cytogenetics,andmolecularmutationscreening.Furthermore,thepotentialofhigh-throughputsequencing
should be evaluated for diagnosis and follow-up of patients with B-lineage ALL.
1.Introduction
Acute lymphoblastic leukemia (ALL) is a heterogeneous
disorder, which consists of various clinical, morphological,
and immunological phenotypes, underpinned by extreme
genetic diversity [2–4]. Adaptation of treatment intensity to
the probability of relapse in the individual patient requires
a thorough understanding of the risks represented by the
various stratiﬁed leukemia subtypes. This has been achieved,
to a large extent, using a broad spectrum of diagnostic tech-
niques including cytomorphology, immunophenotyping,
cytogenetics, ﬂuorescence in situ hybridization (FISH), and
molecular techniques. The panel of known prognostically
important molecular alterations is constantly increasing,
as demonstrated by the recent detection of alterations of
TGF-beta and PI3K-AKT pathway genes and prognostically
adverse deletions at 6q15-16 in T-ALL [5]. In Philadelphia-
positive (B-lineage) ALL, deletions of the IKZF1 gene confer
a more adverse prognosis [6, 7]. Genetic alterations are
now detectable in most ALL patients, when cytogenetic and
molecular techniques are combined. These genetic alter-
ations are linked to distinct clinical proﬁles and show speciﬁc
interaction with other mutation types [8]. Following the
success of the tyrosine kinase inhibitor (TKI) imatinib
in chronic myeloid leukemia (CML), research focused on
targeted therapy strategies for Ph-positive ALL and other
ALL subtypes [9–13]. Imatinib has since become part of pre-
and posttransplant treatment for patients with Ph-positive
ALL [13, 14]. Rituximab was included in treatment of
CD20-positive ALL [15–17]. This paper characterizes the2 Advances in Hematology
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Figure 1: Classiﬁcation of diﬀerent B-lineage ALL/LBL entities according to WHO, 2008 [1].
most important molecular markers in patients with acute
lymphoblastic leukemia, paying attention to their impact for
treatment decisions, and discusses methods for their detec-
tion.
2. B-Lineage Acute Lymphoblastic
Leukemia (ALL)
According to the WHO classiﬁcation published in 2008 [1],
diﬀerent reciprocal rearrangements form the category “B-
lymphoblastic leukemia/lymphoma with recurrent genetic
abnormalities” (Figure 1). Many of these genetic alterations
provide useful markers to monitor the minimal residual
disease (MRD) load [18].
2.1. Philadelphia-Positive ALL. In Ph-positive ALL, the
t(9;22)(q34;q11.2)/BCR-ABL1 can be detected with chro-
mosome banding analysis in 95% of cases, but due to
chromosome preparation, there is a latency of some days
untilresultsareavailable,andtheBCR-ABL1rearrangements
are cryptic in around 5% of all cases. Thus, interphase FISH
or PCR for BCR-ABL1 should be performed in every case of
B-lineage ALL. Since imatinib has been added to intensiﬁed
chemotherapy [19], prognosis of this previously highly
adverse subgroup has been signiﬁcantly improved. RT-PCR
analysis allows a correct detection and classiﬁcation of all
cases according to the breakpoints (m-BCR in the majority
of cases; M-BCR in ∼30% of cases). Deletions of the IKZF1
gene confer an adverse risk proﬁle in Ph-positive ALL [6, 7].
TheIKZF1genehasacodingfunctionforatranscriptionreg-
ulator involved in T- and B-cell diﬀerentiation.
2.2. Burkitt Lymphoma/Mature B-ALL. Burkitt lymphoma/
mature B-ALL is part of the category “mature lymphatic
neoplasms” according to the revised WHO classiﬁcation
[1]. The most frequent is the t(8;14)(q24;q32)/IGH-MYC
rearrangement [20]. Interphase FISH detects the diverse
MYC rearrangements irrespective of the involved partner
chromosomes, but can as well identify speciﬁc MYC rear-
rangements. PCR is less suitable for this purpose due to the
heterogeneous breakpoints. The large and rapidly increasing
tumor burden in Burkitt lymphoma can progress quickly
to cause life-threatening complications and thus requires
immediate therapeutic intervention. Therefore, interphase
FISH analysis screening for MYC rearrangements should be
performed without delay in all suspicious cases (highly ele-
vated LDH, strongly basophilic and vacuolated cytoplasm of
thelymphoblasts,oralargelymphomaloadwhichdeveloped
over a short time span). As endemic EBV-related BurkittAdvances in Hematology 3
lymphoma occurs most commonly in malaria-endemic and
resource-poor areas, where facilities for FISH may be
unavailable, characteristic morphologic appearances on cy-
tologyandhistologystillhaveanimportantrolefordiagnosis
of this particular lymphoma subtype.
2.3. Other Recurrent Mutations in B-Lineage ALL. The most
frequent MLL rearrangement in ALL is the t(4;11)(q21;q23)/
MLL-AFF1, but various other partner genes that can rear-
range with MLL/11q23 have been identiﬁed [21]. In gen-
eral, 11q23/MLL rearrangements confer adverse prognostic
implications, just as in AML [1]. The search for the MLL
rearrangementscanbedonewithinterphaseFISH,whileRT-
PCRcanbedeployedtodetectmanyspeciﬁcrearrangements.
The t(1;19)(q23;p13)/E2A-PBX1 translocation characterizes
25% of pediatric precursor B-lineage ALL and confers a poor
prognosis.
In pediatric B-lineage ALL, the prognostically favorable
t(12;21)(p13;q22)/ETV6-RUNX1 (TEL-AML1) fusion is the
most frequent recurrent translocation and occurs in approx-
imately25%ofprecursorB-lineageALLcases.Therespective
gene fusion cannot be detected with chromosome banding
analysis, whereas interphase FISH or RT-PCR can reveal this
reciprocal rearrangement without diﬃculties. Screening for
the respective gene fusion is mandatory in children with B-
lineage ALL as it confers a favorable prognostic impact [22].
Kuiper et al. performed an evaluation of risk parameters
in pediatric patients with precursor B-lineage ALL. In a mul-
tivariate model, the presence of IKZF1 deletions remained
the strongest predictive factor for relapse-free and overall
survival(P < 0.001),therebysurpassingpreviouslyidentiﬁed
prognostic factors,including the presenceof BCR-ABL1gene
fusions, DNA index, age, and white blood cell count [23].
3.TargetedStrategiesinB-LineageALL
3.1. Tyrosine Kinase Inhibitors. Following the success of ima-
tinib in CML, TKIs were evaluated for BCR-ABL1-positive
ALL. Concurrent or alternating combination of imatinib
with intensive chemotherapy for remission induction and
consolidation was able to achieve morphologic remission
in 95–100% and molecular remission in ∼50% of adults
with Philadelphia-positive ALL [12–14, 24]. Outcomes were
signiﬁcantly improved as compared with historical controls
who received similar chemotherapy regimens but no ima-
tinib [25]. Presently, imatinib combined with chemotherapy
is standard for Ph-positive ALL proceeding to a possi-
ble transplantation [26]. Since most adult patients would
relapse after chemotherapeutic treatment alone, allogeneic
HSCT is still being recommended for adult patients with
Philadelphia-positive ALL in ﬁrst CR [25]. Also in the
posttransplant period, imatinib has been integrated for
prophylactic reasons [11].
Other options for Ph-positive ALL include the use of
second-generationTKIs,whichhavehigherBCR-ABL1aﬃn-
ity and are eﬀective in many patients with resistance to ﬁrst-
generation TKIs, for example, due to de novo variant BCR-
ABL1 isoforms or imatinib resistance-conferring mutations
at the BCR-ABL1 kinase domain. Ottmann et al. evaluated
the success of dasatinib in 36 patients with Ph-positive
ALL who were refractory or intolerant to imatinib. Major
hematologic responses (MHRs) were achieved in 42% of
patients with a median interval to MHR of 1.8 months.
Among patients who achieved MHR, response duration
ranged up to 8.7 months. Ten of the 15 patients (67%) who
achieved an MHR remained free of progression at the 8-
month follow-up. Complete cytogenetic responses were
attained by 58% of patients. Only 6% of patients discontin-
ued therapy as a result of study-drug toxicity [27].
Unfortunately, the multi-TKI-resistant T315I mutation
develops more frequently and relatively faster in patients
with Philadelphia-positive ALL than in patients with chronic
phase of CML who receive TKI treatment [28, 29]. In a
recently concluded phase I clinical trial, the multikinase and
pan-BCR-ABL1 inhibitor, ponatinib (AP24534) induced a
complete cytogenetic and major molecular response rates of
89% and 78%, respectively, in CML patients with T315I,
and most responses were maintained after 12 months of
follow-up [30, 31]. However, it remains to be seen if these
responses will be conﬁrmed. Additionally, DCC-2036, a new
TKI in a novel class of so-called “switch pocket inhibitors,”
is undergoing trials for patients who carry T315I or who
have failed TKI treatment. DCC-2036 targets a pocket that
governs transition to the active state of ABL1, thus locks the
kinase into its inactive state through a selective, non-ATP-
competitive mechanism [30, 32]. GNF-2, another new agent,
inhibits the T315I kinase by binding to the autoregulatory
allosteric myristate cleft at the N-terminus of ABL1, also
eﬀectively freezing the kinase in its inactive state [30, 33].
These new compounds represent interesting new options for
patients with BCR-ABL1-positive leukemias.
3.2. Monoclonal Antibodies with Anti-CD20 Activity. Ritux-
imab is a chimeric monoclonal antibody directed at the (B
cell) CD20 receptor. Its activity is associated with induction
of antibody-dependent cytotoxicity, or direct apoptosis [34].
As the CD20 antigen is frequently expressed in B-lineage
ALL, rituximab has been successfully combined with inten-
sive chemotherapy regimens in B-lymphatic neoplasms of
low- and of high-grade malignancy. Thomas et al. suggested
the inclusion of rituximab into a modiﬁed hyper-CVAD
regimen (cyclophosphamide, vincristine, doxorubicin, and
dexamethasone) for adolescents and adults with de novo
precursor B-lineage ALL. In patients with CD20 expression,
rituximab improved outcomes compared with the historical
experience using hyper-CVAD alone, with 3-year CR dura-
tion rates of 68% versus 28% in the historical cohort (P <
0.001) [16]. In mature B-ALL (Burkitt lymphoma), survival
ratesincreased>80%withthecombinationofshortintensive
chemotherapy and rituximab [19]. Rituximab can also be
used for intrathecal therapy for CD20-positive ALL pa-
tients with CNS disease failing to respond to intrathecal
chemotherapy [17]. In the allogeneic transplant setting,
Kebriaei et al. incorporated rituximab in the conditioning4 Advances in Hematology
regimens for adolescents and adults with CD20-positive ALL
[35].
3.3. Monoclonal Antibodies with Anti-CD19 Activity. Topp
et al. just recently reported a phase II study in which the
eﬃcacy of the bispeciﬁc single-chain anti-CD19 antibody
blinatumomab was studied [36]. The drug was administered
to21B-lineageALLpatientswithMRDpersistenceorrelapse
after-chemotherapy. Sixteen patients (76%) responded and
became MRD negative. Estimated relapse-free survival at
a median follow-up of 405 days was 78%, and the most
frequent severe adverse eﬀect was a reversible lymphocy-
topenia. The authors concluded that blinatumomab is ef-
ﬁcacious and well tolerated in this subgroup of patients,
after intensive chemotherapy. It was noted that T cells
engaged by blinatumomab seemed capable of eradicating
chemotherapy-resistant tumor cells [36].
3.4. Indication for Allogeneic HSCT in B-Lineage ALL. Con-
ventional practice dictates that ALL patients in 2nd complete
remission (CR2) or beyond invariably require allogeneic
HSCT [37, 38]. Likewise, patients with high-risk disease are
r ec o mme nd edf o rHSCTinCR1.H o w ev e r ,o nac c ounto fthe
good results recently reported for Ph-positive ALL with the
tyrosine kinase inhibitors, there may be a need to reevaluate
the “risk” status of the Philadelphia chromosome in ALL
[10, 39–41]. The GRAAPH study group had examined
imatinib-intensiﬁed chemotherapy and HSCT in 45 adult
Ph-positive ALL patients and reported an overall CR rate of
96%. Among the 22 patients who had donors and received
allogeneic HSCT in CR1, the estimated cumulative inci-
dences of relapse, disease-free survival, and overall survival
were 30%, 51%, and 65%, respectively. These end points
compared very favorably with results obtained in the pre-
imatinib era [12]. The JALSG prospectively treated 80 adult
Ph-positive ALL patients with imatinib-fortiﬁed chemother-
apy and reported a CR rate of 96%. Allogeneic HSCT
was performed for 49 patients. Among the current trial
patients, the probability for OS at 1 year was 73.3% for the
recipients of allogeneic HSCT, and 84.8% for patients
withoutHSCT[13].Schultzetal.evaluatedwhetherimatinib
with an intensive chemotherapy regimen improved outcome
in 92 children and adolescents with Ph-positive ALL and
compared toxicities to 65 Ph-negative ALL patients given the
same chemotherapy without imatinib. Three-year EFS was
similar for patients in the cohort treated with chemotherapy
plus imatinib (88% ± 11%) or sibling donor BMT (57% ±
22%). There were no signiﬁcant toxicities associated with
adding imatinib to intensive chemotherapy [10]. Thus the
outcomes for patients with Ph-positive ALL treated with
imatinib-containingchemotherapywerebecomingmorelike
those for patients with standard risk ALL.
For patients with critical ALL subtypes, it remains to be
seenwhetherfutureMRDstrategiesmightfocusonsubclone
analysis and on tracking all minor and major clones during
the early phases of chemotherapy [42]. This might result
in a higher reliability to predict the relapse risk and might
contribute to identify those patients who might beneﬁt from
an early allogeneic HSCT.
4. T-Lineage Acute Lymphoblastic
Leukemia (T-ALL)
Clonal cytogenetic anomalies are detectable in 50–70% of all
cases of T-cell ALL. Reciprocal translocations usually involve
the T-cell receptor (TCR) genetic loci; TCRA and TCRD
(14q11.2), TCRB (7q35), or TCRG (7q14-15). The partner
genetic loci reported are usually transcription factors partic-
ularly HOX11 (TLX1, 10q24), HOX11L2 (TLX3, 5q35); oth-
ers include the MYC (8q24.1) or TAL1 (1p32) genes. Other
fusion genes are, for example, CALM-AF10 or NUP214-
ABL1. For molecular MRD measurement, suitable fusion
transcripts are available for only 10–20% of T-ALL patients.
If appropriate targets are available, quantitative real-time
PCRcanachievesensitivityof10−4 to10−5.Inthealternative,
clone-speciﬁc TCR rearrangements of the leukemic T cells
could equally serve for MRD monitoring in remission with
comparable sensitivity. However, ampliﬁcation of clone-
speciﬁc TCR rearrangements is highly laborious as patient-
tailored assays are required. Furthermore, molecular clonal
evolution can lead to false-negative results [43].
4.1. Therapeutic Strategies in T-Lineage ALL. Although cur-
rent treatment protocols result in complete remission in 80–
90%ofadultswithnewlydiagnosedT-cellacutelymphoblas-
tic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL),
approximately half of these patients relapse within the ﬁrst
two years [44]. The prodrug nelarabine is demethylated by
adenosine deaminase to a deoxyguanosine derivative (ara-
G). DeAngelo et al. administered nelarabine to 26 patients
with T-ALL and 13 with T-LBL who were refractory to at
least one multiagent regimen or had relapsed. Cycles were
repeated every three weeks. The complete remission rate was
31%,andthe1-yearoverallsurvivalwas28%.Theoveralltol-
erability was acceptable [45, 46]. Due to the clear antitumor
activity in relapsed/refractory T-ALL/T-LBL, the compound
has been approved by the FDA for patients who failed at least
in two prior regimens [47].
In comparison to B-lineage ALL, it is more diﬃcult to
clarify the prognostic meaning of karyotypes in T-lineage
ALL due to the lower incidence. Normal karyotypes and the
t(10;14)/HOX11-TCRwereshowntobeassociatedwithgood
outcomes in pediatric T-ALL [48].
4.2. Indication for Allogeneic HSCT in T-Lineage ALL. The
use of conventional ALL chemotherapy for T-cell ALL has
been associated with inferior outcomes compared to B-cell
ALL, and thus most T-cell ALL were considered high risk.
However, there have been suggestions of improved outcomes
with more aggressive use of antimetabolite therapy in T-ALL
subgroups [49], largely because these lymphoblasts accumu-
late methotrexate polyglutamates less avidly than blasts of
other subtypes [50]. In the pediatric setting, Schrappe et al.
had indeed shown clinically that high-dose methotrexate
is associated with improved outcomes in T-cell ALL [51].Advances in Hematology 5
Similarly, Pui et al. used increased doses of methotrexate
in the 76 pediatric patients diagnosed with T-ALL and
also achieved improved outcomes, with estimated 10-year
survival rate of 90% [52]. The indication for allogeneic stem
cell transplantation in the ﬁrst remission of T-lineage ALL
is based on the individual risk proﬁles deﬁned, for example,
by the immunophenotype. Thymic (or cortical) T-ALL is
consideredtorepresentstandardriskleukemia,whereasearly
and mature T-ALL confers high risk. Other than that, nonre-
sponse to induction and consolidation regimens or increase
of the MRD load during the course of disease can be
indications to allogeneic transplantation.
5. Monitoringof the MinimalResidual
Disease(MRD)Load
After patients achieve complete remission following either
chemotherapy or HSCT, the MRD load should be serially
assessed [53]. It is thus desirable to identify a suﬃciently
speciﬁc leukemia-speciﬁc marker before-therapy, such as the
BCR-ABL1 fusion. The preferred MRD technique depends
on the desired level of sensitivity or the depth of remission.
Cytogenetics has a sensitivity of 10−2 cells. Interphase ﬂuo-
rescence in situ hybridization (FISH) allows to evaluate 100–
200 cells. Immunophenotyping using multi-parameter ﬂow
cytometry achieves sensitivity levels of 10−3 to 10−5 [54,
55]. Real-time PCR is particularly useful, as it can achieve
as e n s i t i v i t yo f1 0 −4 to 10−6 [56]. Additionally, molecular
techniques can be used to access MRD in ALL even in the
absence of fusion genes, by assessing the levels of clone-
speciﬁc rearrangements of the immunoglobulin or T-cell
receptor [57] and have been introduced into treatment
stratiﬁcation already. In a study from the German Multicen-
ter Study Group for Adult Acute Lymphoblastic Leukemia
(GMALL),atotalof196patientswithstandardriskALLwere
investigated at repeated time points in the ﬁrst year by
quantitative PCR monitoring of clonal immunoglobulin or
TCR rearrangements. Three risk groups could be deﬁned.
Patients with a rapid decline of the MRD load to <10−4 or
below detection limit in the early treatment period (days
11 and 24) were classiﬁed as low risk and had a three-
year relapse rate of 0%. Patients with an MRD of ≥10−4
until week 16 formed the high-risk group with a 3-year
relapse rate of 94%. The remaining patients had an inter-
mediate risk [58]. In another study from the GMALL, post-
consolidationsamplesof105patientswithstandardriskALL
were investigated by real-time quantitative PCR for clonal
immune gene rearrangements. All patients were beyond
the ﬁrst year of chemotherapy, in hematological remission,
and were MRD negative before study entry. The relapse rate
was 61% in patients converting to MRD positivity thereafter,
whereas only 6% of continuously MRD-negative patients
relapsed [59].
Expert panels have already suggested recommendations
on the minimal technical requirements before implemen-
tation of MRD diagnostics into clinical trials and have
standardized criteria for “complete MRD response,” “MRD
persistence,” and “MRD reappearance.” These steps facilitate
the comparison of MRD results between diﬀerent treatment
protocols [60]. The determination of B-cell speciﬁc donor
chimerism may facilitate monitoring and therapeutic deci-
sions in patients with B-lineage ALL in the posttransplant
period [61].
6. Conclusion
In recent years, molecular diagnostics in the acute lym-
phoblastic leukemia have progressed rapidly. PCR-based
analyses in combination with other approaches (cytoge-
netics, FISH, and immunophenotyping) have allowed us
to deﬁne various distinct ALL subtypes, part of which
already deﬁnes separate entities within the WHO classiﬁ-
cation of 2008, for example, the t(9;22)/BCR-ABL1 or the
t(12;21)(p13;q22)/ETV6-RUNX1. Deeper insights into the
networks of molecular markers have facilitated the under-
standing of the heterogeneity of the clinical courses within
distinct genetic subgroups and improved therapeutic deci-
sions, for example, regarding the indication to allogeneic
HSCT within T-lineage ALL [49]. Screening for deletions of
the IKZF1 gene might improve risk stratiﬁcation in patients
with Ph-positive ALL [6, 7]. Distinct levels of the MRD load
as assessed by RQ-PCR have been deﬁned as guidelines for
therapeutic decisions [19, 62]. Molecular diagnostics and
immunophenotyping have become the basis for targeted
therapyinALL,asdemonstratedbytheuseoftyrosinekinase
inhibitors for BCR-ABL1-positive ALL, and rituximab for
CD20-positive B-cell precursor ALL [16] or mature B-ALL/
Burkitt lymphoma [19], which improved the prognosis of
these previously highly adverse subtypes. Screening for BCR-
ABL1 mutations can be helpful to identify patients with
Philadelphia-positive ALL who may have a beneﬁt from sec-
ond tyrosine kinase inhibitors or novel compounds targeting
the T315I. Considering the recent introduction of high-
throughput sequencing into hematological diagnostics [63],
the potential of this novel technology should be explored
for mutation screening, the deﬁnition of new therapeutic
targets, and follow-up diagnostics in the acute lymphoblastic
leukemias.
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